The molecules and pathways that fine-tune innate inflammatory responses mediated by Toll-like receptor 7 (TLR7) remain to be fully elucidated. Using an unbiased genome-scale screen with short hairpin RNA (shRNA), we identified the receptor TREML4 as an essential positive regulator of TLR7 signaling. Macrophages from Treml4 −/− mice were hyporesponsive to TLR7 agonists and failed to produce type I interferons due to impaired phosphorylation of the transcription factor STAT1 by the mitogen-activated protein kinase p38 and decreased recruitment of the adaptor MyD88 to TLR7. TREML4 deficiency reduced the production of inflammatory cytokines and autoantibodies in MRL/lpr mice, which are prone to systemic lupus erythematosus (SLE), and inhibited the antiviral immune response to influenza virus. Our data identify TREML4 as a positive regulator of TLR7 signaling and provide insight into the molecular mechanisms that control antiviral immunity and the development of autoimmunity.
In humans and mice, the Toll-like receptor (TLR) family consists of 13 members that can be categorized into two subgroups on the basis of their cellular location 1 . Cell-surface TLRs (TLR1, TLR2, TLR4, TLR5 and TLR6) recognize various molecules from bacteria and fungi. Intracellular TLRs (TLR3, TLR7, TLR9 and TLR13) recognize nucleic acids: TLR3 recognizes double-stranded RNA; TLR7 recognizes single-stranded RNA (ssRNA); and TLR9 and TLR13 are receptors for double-stranded DNA (dsDNA) and ribosomal RNA, respectively 2 . TLRs are an evolutionarily conserved family of type I transmembrane receptors that have an extracellular domain compromising leucine-rich repeats and a cytoplasmic domain that shares substantial homology with the mammalian type I receptor for interleukin 1 (IL-1) (ref.
3). The TLRs are germline-encoded receptors that recognize myriad conserved microbe-associated molecular patterns found in many different microbes, such as bacteria, fungi, viruses and parasites. The recognition of these patterns by TLRs leads to the initiation of intracellular signaling pathways that elicit the expression of genes encoding inflammatory molecules, such as cytokines essential for host defense. Upon binding their ligands, all TLRs trigger a common signal-transduction pathway that starts with recruitment of the intracellular adaptor MyD88 that mediates phosphorylation of the kinase IRAK1 by IRAK4 (ref. 4). Phosphorylated IRAK1 associates with the signaling protein TRAF6, which mediates the activation of mitogen-activated protein kinases (MAPKs) and subsequent activation of transcription factors that promote the expression of cytokine-encoding genes.
Activation by TLRs is central to early host defense; however, excessive activation of the TLR signaling pathway can contribute to chronic inflammatory diseases 5 . Thus, TLR signaling must be under tight positive and negative regulation to maintain immunotolerance. Members of the TREM ('triggering receptor expressed on myeloid cells') family of receptors have been shown to regulate innate immune responses by amplifying or dampening TLR-induced signals [6] [7] [8] [9] . TREM and TREML are structurally similar families of receptors that consist of a single extracellular variable-type immunoglobulin-like domain, a transmembrane domain and a short cytoplasmic tail lacking any known signaling motifs; these receptors are expressed predominantly on myeloid cells 10 . TREM1 promotes the inflammatory response to bacteria and the TLR4 ligand lipopolysaccharide (LPS) 6 . In contrast, TREM2 and TREML1 suppress TLR-induced signals and protect against autoimmunity [11] [12] [13] . The inhibitory TLR signals mediated by TREM2 depend upon its interaction with DAP12, a transmembraneanchored signaling adaptor containing an immunoreceptor tyrosine-based activation motif within its cytoplasmic domain 8, 14 . The ligands for TREM receptors have remained largely elusive; however, several reports suggest that TREM receptors can bind to microbial and host molecules. TREML4 has been shown to bind to late apoptotic and necrotic cells 15 , and TREML1 has been shown to bind to fibrinogen 11 , whereas TREM1 and TREM2 recognize anionic ligands from bacteria 16 .
TLRs have also been linked to the development and exacerbation of chronic inflammatory syndromes and autoimmunity through their inappropriate activation by endogenous self ligands, such as nucleic acids released from necrotic cells; this includes the development and progression of the autoimmune disease systemic lupus erythematosus (SLE) 2,5, 17 . Dysregulated activation of TLR7 has been linked to the 4 9 6 VOLUME 16 NUMBER 5 MAY 2015 nature immunology A r t i c l e s pathogenesis of SLE in humans and mice. Male BXSB mice with a Y-linked autoimmune accelerator locus (Yaa) develop spontaneous SLE-like disease due to a duplication of a 4-megabase gene segment containing sequence encoding TLR7 transposed to the Y chromosome 18, 19 . This duplication is responsible for the autoimmune phenotype of Yaa male mice, because a reduction in the copy number of transcripts encoding TLR7 abrogates this disease 20 . Furthermore, the progeny of mice of the MRL/lpr (MRL lymphoproliferation) strain, which spontaneously develop SLE, backcrossed to TLR7-deficient mice have much less renal disease and fewer autoantibodies to RNAassociated autoantigens 21, 22 . Finally, single-nucleotide polymorphisms in the gene encoding TLR7 have been identified that are associated with increased transcript expression and increased risk for SLE in humans 23 . Together these observations indicate that TLR7 signaling is critical for SLE-specific autoimmunity.
To identify genes encoding molecules required for the TLR7-mediated activation of cells of the immune system, we performed a genome-scale RNA-mediated interference (RNAi)-based screen of mouse macrophages and identified TREML4 as a positive regulator of TLR signaling. TREML4 was required for TLR7-mediated responsiveness to TLR7 ligands and promoted TLR7-induced activation and phosphorylation of the MAPK p38 and the transcription factor STAT1 and the trafficking and localization of MyD88 and TLR7 to endosomes. We also found that TREML4 was critical for the antiviral immune response to the ssRNA influenza virus. Finally, TREML4 deficiency ameliorated inflammatory cytokine production and kidney disease in SLE-prone MRL/lpr mice. Thus, our findings demonstrate a critical role for TREML4 in promoting TLR7-mediated cytokine production during antiviral responses and the development of autoimmunity.
RESULTS

TREML4 positively regulates the TLR7 pathway
To identify genes and pathways required for TLR7-induced cell activation, we performed an unbiased genome-scale pooled lentivirus-based RNAi screen with a mouse short hairpin RNA (shRNA) library (with ~4 × 10 4 members) developed by The RNAi Consortium 24, 25 . We used a construct in which expression of enhanced green fluorescent protein (GFP) is driven by the promoter of the gene encoding ELAM-1 ('endothelial leukocyte adhesion molecule 1'), which is responsive to the transcription factor NF-κB (NF-κB-GFP), and stably transfected RAW 264.7 mouse macrophages with this (to generate 'RAW-GFP' reporter cells). We transduced the RAW-GFP cells with the pool of ~4 × 10 4 lentivirus-encoded mouse shRNAs. With this approach, ~8 × 10 3 mouse genes were targeted by five or more independent shRNAs per gene, and cells received an average of ~0.3 shRNAs (multiplicity of infection, 0.3); each shRNA was introduced into ~2 × 10 2 independent cells. We treated the shRNA-transduced cells with the synthetic TLR7-specific agonist gardiquimod (GRD) for 6 h and sorted the cells by flow cytometry into two populations, TNF lo GFP lo and TNF hi GFP hi , on the basis of their expression of tumor-necrosis factor (TNF) and NF-κB-GFP. We then amplified the shRNA sequences by PCR from genomic DNA isolated from the two cell populations and hybridized the products to complementary microarrays. To identify the shRNAs that inhibited GRD-induced expression of TNF and NF-κB (i.e., positive regulators of TLR7 signaling), we measured the overrepresentation of shRNAs that were more often present in the TNF lo GFP lo sorted population of RAW-GFP cells than in the TNF hi GFP hi subset. By this approach, we identified 257 such 'enriched' shRNAs with a difference in abundance of greater than twofold (Fig. 1a and Supplementary Table 1) . In the TNF lo GFP lo subset, we identified enrichment for shRNAs that targeted genes encoding molecules with well-established roles in the TLR7 signaling pathway, such as TLR7, MyD88, IRAK2, IRAK4, TRAF6 and IRF7 (Fig. 1a and Supplementary Table 1 ). In addition, we identified several genes encoding molecules that have not been previously described as positive regulators of TLR7 signaling (Fig. 1a and Supplementary Table 1) . Among these, an shRNA targeting TREML4 had the eleventh greatest enrichment in our RNAi-based screen, among the ~4 × 10 4 shRNAs tested (difference in abundance (log), 3.42-fold; Fig. 1a and Supplementary Table 1) . To confirm the screen results, we independently transduced RAW-GFP reporter cells with lentivirus containing either of two different shRNAs that targeted two distinct regions of Treml4 mRNA and had different sequences in the seed region known to mediate off-target effects. Quantitative PCR and immunoblot analysis of the shRNA-transduced RAW-GFP cells showed that both effectively knocked down expression of Treml4 (Fig. 1b,c) and demonstrated a significant correlation between the reduced expression of Treml4 mRNA and TREML4 protein and diminished expression of TNF and NF-κB-GFP in response to the stimulation of TLR7 (Fig. 1d) . These data demonstrated that TREML4 was a positive regulator of TLR7 signaling. To investigate whether TREML4 regulates the signaling pathways downstream of other TLRs, we transfected RAW-GFP cells with shRNA-encoding viruses to silence the expression of Myd88 or Treml4 and treated the cells with agonists for TLR2-TLR1 (the synthetic lipopeptide Pam 3 CSK 4 ), TLR2-TLR6 (zymosan), TLR3 (the synthetic RNA duplex poly(I:C)), TLR4 (lipopolysaccharide (LPS)), TLR9 (CpG DNA) or TLR13 (rRNA). Silencing of Treml4 expression significantly reduced the ability of RAW-GFP cells to induce expression of NF-κB-GFP and TNF in response to agonists of TLR7, TLR9 and TLR13 but not in response to other TLR ligands (Fig. 1e) . These data demonstrated that TREML4 was a positive regulator for a limited sub-group of intracellular TLRs in RAW macrophages.
We next investigated whether overexpression of TREML4 could amplify TLR signaling. We transfected human embryonic kidney (HEK) cells stably expressing TREML4 with plasmids containing cDNA encoding TLR2, TLR3, TLR4, TLR7, TLR9 or TLR13 and stimulated the cells with the cognate agonists of these TLRs. Overexpression of TREML4 significantly amplified TLR7-, TLR9-and TLR13-mediated induction of IL8 mRNA in HEK cells transfected to express TLR7, TLR9 or TLR13, respectively ( Fig. 1f and Supplementary Fig. 1a) . HEK cells overexpressing TREML4 in the absence of TLR7 overexpression did not produce IL8 mRNA in response to TLR7 agonists (Fig. 1f) , which indicated that TREML4 was not activated directly by TLR7 ligands.
To investigate whether TREML4 regulates TLR7 signaling through its association with intracellular adaptors, we transfected TLR7-expressing HEK cells with plasmid encoding wild-type TREML4, TREML4 lacking the cytoplasmic domain or TREML4 containing a point substitution in the transmembrane domain (with replacement of leucine for the lysine at position 210) and measured IL8 mRNA following stimulation with the TLR7 ligand GRD. We found only a modest requirement for the cytosolic domain of TREML4 for TLR7 signaling (Fig. 1g) . In contrast, HEK cells expressing TREML4 lacking the cytoplasmic domain had significant impairment in TLR7-induced expression of IL8 mRNA compared with that of HEK cells expressing wild-type TREML4 (Fig. 1g) , which indicated that the charged lysine residue in the transmembrane domain was required for the TREML4-mediated amplification of TLR7 signaling.
Human and mouse TREML4 share about 40% amino acid identity; however, human TREML4 is truncated compared with its mouse npg counterpart due to insertion of a stop codon just downstream of sequence encoding the charged lysine residue in the transmembrane domain. To determine whether human TREML4 regulates TLR7 signaling, we silenced TREML4 expression in the human monocyte cell line THP-1 by lentiviral transduction of TREML4-specific shRNA. THP-1 cells in which TREML4 was silenced had lower expression of IL8 mRNA following stimulation with the TLR7 ligand GRD than did THP-1 cells transduced with nontargeting control shRNA (Fig. 1h) , which indicated an evolutionarily conserved function for TREML4 in the regulation of TLR7 signaling.
Because TREML4 binds to late apoptotic and necrotic cells 15 and because nucleic acids can accumulate in apoptotic blebs or leak from necrotic cells, we investigated whether nucleic-acid ligands for TLR7, TLR9 and TLR13 could bind to TREML4 to induce TREML4 signaling. Because little is known about the signaling pathways and targets downstream of TREM receptors, we constructed a chimeric protein containing the extracellular domain of TREML4 fused to the intracellular domain of the TNF receptor TNFR1 and overexpressed it in HEK cells. This TREML4-TNFR1 chimeric receptor allowed us to quantify the binding of ligand to TREML4 through induction of the TNFR1-dependent signaling pathway that leads to the activation of NF-κB and expression of IL8 mRNA in HEK cells 26 . The addition of late apoptotic cells to the culture medium induced robust induction of IL8 mRNA in cells expressing TREML4-TNFR1 but not those expressing a control construct of the C-type lectin receptor dectin-1 fused to TNFR1 ( Supplementary Fig. 1b) ; this indicated a direct interaction between TREML4 and apoptotic cells. In contrast, following stimulation with GRD, CpG DNA or rRNA, we observed only weak induction of IL8 mRNA (less than twofold) in cells transfected to express TREML4-TNFR1 compared with its expression in mock-transfected cells ( Supplementary Fig. 1b) ; this suggested that nucleic acids were not cognate ligands for TREML4. Together these results identified mouse and human TREML4 as positive regulators of signaling via TLR7, TLR9 and TLR13.
TREML4 positively regulates signaling via TLR7, TLR9 and TLR13
We performed quantitative PCR analysis to assess the expression of Treml4 mRNA in various organs of wild-type C57BL/6 mice. Treml4 was expressed mainly in the spleen (Supplementary Fig. 2a ). Treml4 expression was low or absent on endothelial cells, B cells, T cells and natural killer cells but was detectable on macrophages, dendritic cells (DCs), neutrophils, bone marrow-derived DCs (BMDCs) and bone marrow-derived macrophages (Supplementary Fig. 2b ), consistent with published reports suggesting restricted TREML4 expression on splenic macrophages and DCs 15, 27 . In addition, in vitro stimulation with the TLR7 ligand GRD induced a rapid increase in Treml4 mRNA expression in cultured splenic macrophages (Fig. 2a) .
To further investigate the role of TREML4 in regulating TLR7 responses, we generated TREML4-deficient (Treml4 −/− ) mice in which TREML4 expression was ablated by replacement of exons 2-4, which encode most of the extracellular domain, with a neomycinresistance cassette (Fig. 2b,c and Supplementary Fig. 2c ). To determine whether TREML4 was required for TLR7-induced gene expression in splenic macrophages, we measured the induction of (Fig. 2d) . We also stimulated Treml4 +/+ and Treml4 −/− splenic macrophages with agonists for TLR2, TLR3, TLR4, TLR7, TLR9 or TLR13. Treml4 −/− splenic macrophages mice had significant impairment in GRD-, CpG DNA-and rRNA-induced expression of Tnf mRNA compared with that of Treml4 +/+ macrophages ( Fig. 2e) , which confirmed the results obtained by shRNA-mediated knockdown of TREML4 in RAW cells (Fig. 1e) . Enzyme-linked immunosorbent assay (ELISA) of the supernatants of GRD-, CpG DNA-or LPS-stimulated splenic macrophages showed that in response to stimulation with GRD, secretion of TNF, the IL-12 subunit p40 (IL-12p40), interferon-β (IFN-β) and the interferon-inducible chemokine CXCL10 from Treml4 −/− macrophages was significantly impaired compared with that of Treml4 +/+ macrophages ( Fig. 2f) , while in response to stimulation with CpG DNA, the secretion of IFN-β and CXCL10 from Treml4 −/− and Treml4 +/+ macrophages was similar, but the secretion of TNF and IL-12p40 from Treml4 −/− macrophages was significantly impaired compared with that of Treml4 +/+ macrophages (Fig. 2f) .
These results suggested that TLR7-mediated activation of the interferon pathway was TREML4 dependent, while TLR9-mediated activation of the interferon pathway was TREML4 independent. We found no difference between Treml4 +/+ and Treml4 −/− macrophages in their cytokine production in response to stimulation with LPS ( Fig. 2f) , which indicated that TREML4 was not involved in regulating the TLR4 pathway.
We also investigated whether TREML4 modified TLR-induced cytokine production in neutrophils. We isolated CD11b + Ly6g + cells (neutrophils) from the bone marrow of Treml4 −/− mice by magnetic bead-based negative selection and found that these cells had significant impairment in GRD-and rRNA-induced expression of Cxcl2 mRNA compared with that of wild-type neutrophils (P < 0.01 (Mann-Whitney test); Supplementary Fig. 2d ), which suggested that the TLR7-or TLR13-mediated induction of Cxcl2 in neutrophils was TREML4 dependent. In contrast, Treml4 −/− neutrophils migrated normally in response to the peptide chemoattractant fMLP (formyl-methionylleucyl-phenylalanine) in a Transwell chemotaxis assay and had normal ability to ingest opsonized latex beads by phagocytosis compared with that of wild-type neutrophils (Supplementary Fig. 2e,f) ; this suggested that the migration and phagocytic pathways in neutrophils were TREML4 independent. Collectively, these data indicated that TREML4 was a nonredundant positive regulator of signaling via TLR7, TLR9 and TLR13 in splenic macrophages and neutrophils.
TREML4 is critical for responses to ssRNA and influenza virus To investigate whether TREML4 also regulated TLR7 responses to other synthetic and natural ligands, such as the synthetic imidazoquinoline compound R-848 and the ssRNA influenza virus 28 , we injected GRD, R-848, CpG DNA or LPS intravenously or live influenza virus strain A/Puerto Rico/8/34 (PR8) intranasally into Treml4 +/+ and Treml4 −/− mice and used quantitative PCR analysis, flow cytometry and ELISA to assess induction of the expression of TNF, IL-12p40 (encoded by Il12b), IFN-β and CXCL10 (at the level of mRNA and protein) in the spleen and serum at 8 h after injection. Splenocytes from Treml4 +/+ mice given injection of GRD, R-848 or influenza virus had high expression of Tnf, Il12b, Ifnb and Cxcl10 mRNA (Fig. 3a) . In contrast, splenocytes isolated from Treml4 −/− mice given injection of GRD, R-848 or influenza virus showed marked impairment in the expression of these A r t i c l e s inflammatory cytokine-encoding mRNAs (Fig. 3a) . Intracellular flow cytometry showed that F4/80 hi CD11b lo CD11c − splenic macrophages from Treml4 −/− mice given injection of GRD, R-848, influenza virus or CpG DNA produced significantly less TNF protein than did their Treml4 +/+ counterparts (Fig. 3b) . The amount of TNF or IL-12p40 protein in the serum was significantly lower in Treml4 −/− mice than in Treml4 +/+ mice following injection of GRD, R-848, CpG DNA, LPS or influenza virus (Fig. 3c) . The serum concentration of IFN-β and CXCL10 was significantly lower in Treml4 −/− mice given injection of GRD, R-848 or influenza virus than in their Treml4 +/+ counterparts, but expression of these was induced by CpG DNA or LPS at similar level in Treml4 −/− cells and Treml4 +/+ cells (Fig. 3c) , which indicated that the TLR7-mediated activation of the interferon pathway in vivo was TREML4 dependent, while the TLR9-or TLR4-mediated activation of the interferon pathway in vivo was TREML4 independent.
To further investigate the role of TREML4 in the antiviral host defense against influenza virus, we monitored weight loss and viral load in Treml4 +/+ and Treml4 −/− mice infected intranasally with a sublethal dose of influenza virus. Treml4 −/− mice lost weight with kinetics similar to the weight loss of their Treml4 +/+ littermates during the first week of infection (Fig. 3d) . However, Treml4 −/− mice continued to lose weight by day 9 after infection, while the weight of the Treml4 +/+ mice plateaued and then began to gain steadily (Fig. 3d) . Wild-type mice cleared the influenza virus between 10 d and 14 d after primary infection, and most Treml4 +/+ mice survived, while the viral burden in the lungs of Treml4 −/− mice was significantly higher than that of Treml4 +/+ mice at day 10, and a majority of the Treml4 −/− mice succumbed to infection (Fig. 3e,f) . Together these data demonstrated that TREML4 was needed to control the early antiviral response to intranasal infection with influenza virus and to restrict the viral load in the lungs of infected mice.
To determine whether TREML4 was required for the immune response to other pathogenic viruses, we measured the expression of Tnf mRNA by quantitative PCR in splenic macrophages isolated from wild-type and Treml4 −/− mice and then cultured with vesicular stomatitis virus (a ssRNA virus) or cytomegalovirus (a dsDNA virus). Treml4 −/− macrophages had significant impairment in Tnf mRNA expression induced by vesicular stomatitis virus or cytomegalovirus compared with that of wild-type macrophages (P < 0.01 (MannWhitney test); Supplementary Fig. 3a) . This suggested that TREML4 To determine whether the TREML4 deficiency in Treml4 −/− mice had affected the cellular expression of TLR7 and/or members of the TLR7 signaling pathway, we assessed the expression of TLR7 in splenic macrophages and DCs from Treml4 −/− mice. As shown by intracellular flow cytometry, TLR7 expression in Treml4 −/− cells was similar to that in wild-type cells (Supplementary Fig. 3b ). In addition, we found that untreated splenic macrophages from wild-type and Treml4 −/− mice expressed similar amounts of genes encoding molecules critical for TLR7 signaling, such as Tlr7, Myd88, Irak1, Irak3, Irak4, Traf6, Tbk1, Syk, Dap12, Irf5, Irf7, Stat1 and Stat2 (Supplementary Fig. 3c ), which suggested that decreased expression of TLR7 or other components of the TLR7 pathway did not account for the observed hyporesponsiveness of Treml4 −/− mice to challenge with GRD, R-848 or influenza virus. Collectively, these data demonstrated an essential role for TREML4 in the antiviral host response to infection with influenza virus.
TREML4 controls the activation of MAPKs and STAT1
We next assessed the molecular mechanism of the hyporesponsiveness of Treml4 −/− macrophages to TLR7 agonists. To determine whether TREML4 regulates TLR ligand-induced activation of MAPKs, we prepared BMDCs from Treml4 +/+ and Treml4 −/− mice and stimulated the cells with LPS, GRD or CpG DNA, then assessed, by intracellular flow cytometry, the accumulation of phosphorylated kinases Erk1 and Erk2 (collectively called 'p44p42' here) and phosphorylated p38. Stimulation with GRD caused a rapid increase (within 15 min) in phosphorylated p44p42 and phosphorylated p38 in Treml4 +/+ BMDCs but not in Treml4 −/− BMDCs (Fig. 4a,b) . Following stimulation with CpG DNA, the phosphorylation of p44p42 was impaired in Treml4 −/− BMDCs compared with that in their Treml4 +/+ counterparts, but the phosphorylation of p38 was not (Fig. 4a,b) ; this suggested that TREML4 regulated the TLR7 and TLR9 signaling pathways differently. We observed no difference in the ability of LPS to activate MAPKs in Treml4 +/+ BMDCs versus Treml4 −/− BMDCs (Fig. 4a,b) .
Activation of the transcription factor STAT1 is required for the production of interferons and interferon-regulated genes. Full activation of STAT1 occurs by phosphorylation of its Ser727 and Tyr701 residues 29 . Phosphorylation of STAT1 at Ser727 is mediated by TLRinduced p38, while phosphorylation of STAT1 at Tyr701 is dependent on autocrine signaling via type I interferons 30 . Thus, phosphorylation of STAT1 at Ser727 is TLR dependent and interferon independent, while phosphorylation of STAT1 at Tyr701 is TLR independent and interferon dependent. To determine whether TREML4 regulates the TLR7-induced phosphorylation of STAT1 at Ser727, we stimulated Treml4 +/+ and Treml4 −/− BMDCs with LPS, GRD or CpG DNA and assessed by intracellular flow cytometry the induction of such phosphorylation. We observed this phosphorylation in Treml4 +/+ BMDCs stimulated with LPS, GRD or CpG DNA and in Treml4 −/− BMDCs stimulated with LPS or CpG DNA but not in Treml4 −/− BMDCs stimulated with GRD (Fig. 4c) . These data indicated that the TLR7-mediated activation of p38 and phosphorylation of STAT1 at Ser727 were TREML4 dependent, while the TLR4-or TLR9-mediated activation of p38 and STAT1 was TREML4 independent. In addition, we found that the phosphorylation of STAT1 at Tyr701 was significantly impaired in Treml4 −/− BMDCs treated with GRD compared with that in their Treml4 +/+ counterparts (Fig. 4d) , which suggested that TREML4 also amplified signaling via the IFNAR1 receptor for interferons. Because expression of the genes encoding IFN-α, IFN-β and CXCL10 is induced by STAT1, these observations were consistent with the reduced induction of these genes in response to stimulation of TLR7 but not in response to stimulation of TLR4 or TLR9 and suggested that TREML4 might mediate the cross-talk among the TLR, interferon and STAT1 signaling pathways 31 .
TREML4 regulates trafficking of MyD88 and TLR7
To determine whether TREML4 regulates the intracellular trafficking of MyD88 to TLR7, we investigated whether TLR7 and MyD88 interacted following stimulation with GRD. TLR7 and MyD88 immunoprecipitated together in GRD-stimulated Treml4 +/+ BMDCs, while we did not observe this association in Treml4 −/− BMDCs (Fig. 5a) . The binding and recruitment of MyD88 to TLR7 was TREML4 dependent (Fig. 5a) . We also assessed by confocal microscopy the recruitment of MyD88 to TLR7 in BMDCs stimulated for 5 or 15 min with GRD and stained with fluorescence-labeled antibody to TLR7 (anti-TLR7) and anti-Myd88. We observed significant impairment in the trafficking and co-localization of MyD88 and TLR7 in Treml4 −/− BMDCs compared with that in Treml4 +/+ BMDCs (Fig. 5b) , which suggested that TREML4 regulated TLR7 signaling by controlling the recruitment of MyD88 to TLR7. To investigate whether TREML4 regulates the trafficking of TLR7 from the endoplasmic reticulum to endosomal and lysosmal compartments after stimulation, we stimulated Treml4 +/+ and Treml4 −/− BMDCs for 5 or 15 min with GRD, followed by staining with fluorescence-labeled anti-TLR7 or antibody to the endosome marker EEA1 or the lysosomal-associated membrane protein LAMP-1. Confocal microscopy showed significant impairment in the trafficking of TLR7 to EEA1 or LAMP-1 and the co-localization of TLR7 and EEA1 or LAMP-1 in Treml4 −/− BMDCs compared with that in Treml4 +/+ BMDCs (Fig. 5c) . Together these results demonstrated that TREML4 regulated TLR7 signaling by controlling the recruitment of TLR7 to endosomes and lysosomes, where it interacted with MyD88 to initiate signaling.
TREML4-deficiency reduces autoimmunity in mice
To assess the effect of TREML4 deficiency on autoimmunity, we backcrossed Treml4 −/− mice to MRL/lpr mice (which spontaneously develop an autoimmune disease with clinical features similar to human SLE, including autoantibody generation, activation of cells of the immune system and lethal glomerulonephritis) for eight generations. We used a HEp-2 antinuclear antibody (ANA) indirect fluorescent antibody assay for detecting antibodies to both RNA-and DNA-containing autoantigens in the serum of Treml4 −/− MRL/lpr mice and Treml4 +/+ MRL/lpr mice. At 16 weeks of age, serum from most Treml4 +/+ MRL/lpr mice (~96%) produced a homogenous pattern (anti-DNA) or speckled pattern (anti-RNA) of nuclear ANAs, while only 40% of serum samples from Treml4 −/− MRL/lpr mice showed proof of the nuclear production of ANAs (Fig. 6a) . ELISA of autoantibodies to nucleosomes, which detects autoantibodies to histones and dsDNA, showed a significantly lower concentration of autoantibodies in Treml4 −/− MRL/lpr mice than in Treml4 +/+ MRL/lpr mice (Fig. 6b) . ELISA to quantify autoantibodies to dsDNA and the RNA-containing autoantigen Sm-RNP showed that the generation of autoantibodies to DNA and Sm-RNP was significantly lower in Treml4 −/− MRL/lpr mice than in Treml4 +/+ MRL/lpr mice (Fig. 6c,d ). In addition, the highly specific Crithidia luciliae immunofluorescence assay showed substantially less binding of autoantibodies to the dsDNA of the C. luciliae kinetoplast in serum from Treml4 −/− MRL/lpr mice than in that from Treml4 +/+ MRL/lpr mice (data not shown). These results were consistent with published reports demonstrating impairment in the generation of autoantibodies to RNA-and DNA-containing autoantigens in MRL/lpr mice deficient in TLR7 signaling and TLR9 signaling 21 .
We observed significantly fewer CD4 + T cells, CD8 + T cells and plasmacytoid DCs in the spleen and lymph nodes of Treml4 −/− MRL/lpr mice than in those of Treml4 +/+ MRL/lpr mice (Fig. 6e) , as well as fewer activated CD44 + CD4 + T cells in the spleen of Treml4 −/− MRL/lpr mice than in that of Treml4 +/+ MRL/lpr mice (Fig. 6f) . Splenocytes from Treml4 −/− MRL/lpr mice had significantly lower expression of Cxcl10, Il1a, Il1b, Tnf, Il12b, Ifnb and Ifna mRNA than did those from Treml4 +/+ MRL/lpr mice (Fig. 6g) , and the concentration of IFN-α in the serum was significantly lower in Treml4 −/− MRL/ lpr mice than in Treml4 +/+ MRL/lpr mice (Fig. 6h) . Glomerular size, cellularity and deposition of protein in periodic acid Schiff-stained kidney sections were diminished in Treml4 −/− MRL/lpr mice compared with that in Treml4 +/+ MRL/lpr mice (Fig. 6i) . Furthermore, the composite renal disease score, which includes several parameters of nephritis (such as glomerular deposition of immunoglobulin G, proteinuria and blood urea nitrogen concentration), was significantly lower in Treml4 −/− MRL/lpr mice than in Treml4 +/+ MRL/lpr mice (Fig. 6j) . Consistent with their diminished kidney disease, Treml4 −/− MRL/lpr mice showed significantly better survival (~88% survival at 26 weeks) than did Treml4 +/+ MRL/lpr mice (~50% survival at 26 weeks) (Fig. 6k) . Finally, both male Treml4 −/− MRL/lpr mice and female Treml4 −/− MRL/lpr mice were equally protected against SLE, including autoantibody generation, activation of cells of the immune system, inflammatory cytokine production and nephritis (data not shown). Collectively, these data demonstrated an essential role for TREML4 in the regulation of autoimmunity. 
DISCUSSION
The data presented here have provided new insight into the understanding of signaling through the endosomal TLRs TLR7 and TLR9. We found that TREML4 positively regulated the activation of macrophages, DCs and neutrophils by amplifying the TLR7-mediated production of inflammatory cytokines, such as type I interferons, during antiviral responses and autoimmune disease. TREML4 amplified TLR7 signaling by promoting phosphorylation and activation of p38 and STAT1. Furthermore, TREML4 expression was essential for the recruitment of MyD88 to TLR7 at endosomes. Together these data demonstrated an important role for TREML4 in the regulation of TLR7 signaling and that its expression in vivo was required for the antiviral host defense against influenza virus and for the promotion of TLR7-mediated autoimmune disease. Our findings have demonstrated a unique specificity for TREML4 in promoting the activation of DCs, macrophages and neutrophils by ligands for TLR7, TLR9 and TLR13 but not those for other TLRs. TREML4 promoted the induction of STAT1-dependent genes, such as those encoding type I interferons, in TLR7-stimulated DCs but not in TLR9-stimulated DCs. Full activation of STAT1 occurs via phosphorylation of Ser727 by TLR7-induced p38 and of Tyr701 by autocrine signaling via IFNAR1. We found that TREML4 promoted both the TLR7-p38-dependent phosphorylation of Ser727 and the IFNAR1-dependent phosphorylation of Tyr701, which indicated that in addition to promoting TLR7 signaling, TREML4 also amplified the IFNAR1 pathway, and suggested that TREML4 may regulate the cross-talk among the TLR, IFNAR1 and STAT1 signaling pathways 31 .
The ligands for receptors of the TREM family have largely remained elusive. Our data obtained with HEK cells transfected to express a chimeric TREML4-TNFR1 reporter suggested that none of the TLR ligands tested bound to or activated TREML4 directly. While the TREML4 ligand remains unknown, we did demonstrate that amplification of TLR7 signaling by TREML4 was dependent on the charged lysine residue present in the transmembrane domain of TREML4. This cationic lysine residue is present in the transmembrane domain of several members of the TREM family, including TREM1, TREM2, TREM3 and pDC-TREM, and has been shown to be required for association with the adaptor DAP12 ('DNAX-activation protein, 12 kDa'), which bears an immunoreceptor tyrosine-based activation motif 32 . TREML4 also associates with DAP12 but not with DAP10 or Fc receptors 15 . DAP12-deficient macrophages have been shown to secrete increased amounts of cytokines after TLR stimulation, which indicates that receptors that pair with DAP12 negatively regulate signaling through TLRs 14 . Those data are in agreement with studies showing that the receptor TREM2, which pairs with DAP12, negatively regulates TLR signaling 33 . Furthermore, those patients with Nasu-Hakola disease who develop bone cysts and presenile dementia have been found to have loss-of-function mutations in either the gene encoding DAP12 or that encoding TREM2, which indicates that this receptor-signaling adaptor pair is crucial for bone remodeling and brain function 34, 35 . In addition, variants in TREM2 have been associated with an increased risk of Alzheimer's disease 12, 13 . Thus, DAP12 and TREM2 negatively regulate inflammatory pathways; however, what remains unclear is how DAP12 signaling downstream of TREM1 and TREML4 is involved in the positive regulation of TLR signaling npg pathways. One possibility is that TREM receptors may regulate TLR signaling in a DAP12-independent manner. Indeed, soluble forms of TREM1 and TREM2 are released from cells activated by inflammatory stimulation, and a soluble form of TREML4 has been shown to bind to dead cells 36, 37 . These soluble TREM receptors may interact with asyet-unidentified ligands on cells to amplify or suppress inflammatory pathways. Additional studies are needed to address whether different signaling pathways are activated via soluble forms of TREM receptors versus the membrane-bound forms. While the overexpression and genetic loss-of-function experiments indicated that TREML4 was essential in promoting TLR7 signaling, because the ligand for TREML4 is unknown, we were unable to induce TREML4 signaling directly and identify its function(s) in the absence of TLR7 signaling. The development of specific agonists of TREML4 will be very useful as a tool with which to delineate the key downstream signaling pathways responsible for TREML4-mediated amplification of signaling via TLRs and interferons, while antagonists of TREML4 may have therapeutic applications in dampening inflammatory autoimmune diseases. It is also possible that no endogenous ligands exist for TREML4 and perhaps, like other receptors such as TREM2, its expression and signaling through adaptors controls cellular functions such as transport to the cell surface, shedding of soluble receptors from the ectodomain, phagocytosis and the expression of co-stimulatory molecules 38 . We found that similar to mouse TREML4, human TREML4 also positively regulated TLR7 signaling. Patients with acute coronary syndrome and coronary artery calcification have high expression of human TREML4 (refs. 39,40) . Such results are consistent with the proposal of a role for TREML4 as an activating receptor and indicate it might have a role in cardiovascular disease. Together these data suggest that increased TREML4 expression could be a useful biomarker for the early detection of acute and chronic inflammatory disease in patients.
The 'rescue' of the autoimmune phenotype in MRL/lpr mice by deletion of TREML4 is similar to results obtained with MRL/lpr mice lacking MyD88, TLR7, or both TLR7 and TLR9, or MRL/lpr mice given injection of dual antagonists of TLR7-TLR9, which have much lower autoantibody titers to the autoantigens DNA and RNA and also have ameliorated disease 21, [41] [42] [43] [44] . We propose that in the absence of TREML4, MyD88 fails to traffic to TLR7, which results in disruption of the activation of p38 and the phosphorylation of STAT1. Similar to STAT1-deficient mice, mice lacking TREML4 are unable to produce interferon or express interferon-inducible genes in response to TLR7 stimulation and are protected from the development of lupus disease 45 . Together these data demonstrate critical role for TREML4 in regulating TLR7 signaling and that therapeutic blockade of TREML4 holds considerable promise for the prevention of autoimmunity.
Although it is possible that therapy with antagonistic anti-TREML4 could be used to prevent and/or dampen lupus disease, caution may be warranted, as chronic therapeutic inhibition of signaling via TLR7 and TLR9 could potentially lead to increased susceptibility to infectious complications with microbial pathogens. While mice with mutations in genes encoding specific TLRs or key TLR signaling molecules are more susceptible to infection, their clinical disease signs are often mild and occur mainly in experimental settings with high doses of pathogens. Furthermore, these mice are healthy in standard husbandry conditions, which suggests that other pathways can overcome these defects. This is true for infection with influenza virus, which is controlled by at least three different classes of pattern-recognition receptors, including TLR7, TLR8 and NLRP3 (a member of the RIG-I (retinoic acid-inducible gene I) and Nod (nucleotide-binding oligomerization domain)-like receptor family). The recognition of ssRNA from influenza virus by TLR7 mediates signaling that leads to the production of antiviral cytokines, such as type I interferons, but TLR7 signaling is not needed for an intact CD8 + T cell response. Instead, signaling via NLPR3 and the cytokine receptor IL-1R in DCs generates protective adaptive immunity by promoting CD8 + T cell responses to influenza virus. Finally, increased susceptibility to viral infections has not been noted in patients with SLE who have been treated with hydroxychloroquine, a molecule that raises lysosomal pH and inhibits TLR signaling, or in patients with SLE enrolled in clinical trials who have received inhibitors of TLR7 and TLR9. Thus, while mice deficient in TREML4 are more susceptible to infection with influenza virus, additional studies are needed for full analysis of the role of TREML4 in antiviral host defense to determine whether it may be possible to therapeutically inhibit TREML4-mediated TLR7 signaling in the long term for the treatment of autoimmune diseases without the potentially harmful complications that could arise from viral infections.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Reagents. Reagents were from Sigma-Aldrich unless stated otherwise. DMEM and RPMI-1640 medium were from Invitrogen. Complete medium consisted of RPMI-1640 medium or DMEM supplemented with 100 U/ml penicillin, 100 U/ml streptomycin, 2 mM l-glutamine and 10% FCS. The following antibodies were used in this study: anti-TREML4 (16E5; BioLegend), anti-GAPDH (71.1; Sigma-Aldrich), anti-TNF (MP6-XT22; R&D Systems), antibody to STAT1 phosphorylated at Tyr701 (58D6; Cell Signaling), antibody to STAT1 phosphorylated at Ser727 (D3B7; Cell Signaling), antibody to phosphorylated p44p42 (D13.14.4E; Cell Signaling), antibody to phosphorylated p38 (28B10; Cell Signaling), anti-MyD88 (2E9C2; Thermo Scientific), anti-TLR7 (PA5-23489; Thermo Scientific), anti-TLR7 (PA5-23126), antiCD11b (M1/70; eBioscience), anti-CD11c (N418; eBioscience), anti-F4/80 (BM8, eBioscience), anti-EEA1 (1G11; eBioscience) and anti-LAMP-1 (1D4B; eBioscience). All TLR agonists were from Invivogen. The HEK293T cell line (HCL4517) was from Fisher Scientific, and human THP-1 cells (TIB-202) were from American Type Culture Collection. All cell lines were determined to be free of mycoplasma by analysis with a mycoplasma-detection PCR Kit (Sigma). Influenza virus strain A/Puerto Rico/8/34 (PR8; VR-1469; American Type Culture Collection) was grown in Madin Darby canine kidney cells in the Means laboratory.
Plasmids. The cDNA encoding mouse TREML4 was provided by H. Hemmi and R. Steinman. Plasmids encoding mouse TLR proteins were obtained from D. Golenbock or were from Invivogen.
Mice. All mice were maintained under micro-isolation in specific pathogenfree conditions at the Massachusetts General Hospital animal facility under a protocol approved by the Institutional Animal Care and Use Committee. Wild-type C57BL/6 mice and SLE-prone MRL/lpr mice were from The Jackson Laboratories. For the generation of TREML4-deficient mice, a targeting vector that contained 6,239 base pairs (bp) of 5′ sequence upstream of the transcriptional start site, 4,366 bp of 3′ sequence downstream of exon 4, and a neomycinresistance cassette replacing exons 2-4 was transfected by electroporation into C57BL/6 embryonic stem cells. Targeted clones were selected in the presence of the antibiotic neomycin and were identified by PCR and Southern blot analysis. Targeted embryonic stem clones were injected into C57BL/6 mice blastocysts by the Knockout Mouse Project at the University of California Davis, which resulted in several lines of chimeric mice that transmitted the disrupted allele through the germline DNA. The TREML4-deficient mice bred at normal Mendelian ratios. Treml4 −/− mice were backcrossed at least eight generations to Fas-deficient, SLE-prone MRL/lpr mice, at which point more than 99.8% of the genome was derived from the MRL/lpr strain (by statistically analysis). These Treml4 −/− MRL/lpr mice were then intercrossed to produce two cohorts of 16 Treml4 +/+ MRL/lpr and 16 Treml4 −/− MRL/lpr mice (32 mice total per genotype), which were analyzed at 16 weeks of age. A third cohort of 47 Treml4 +/+ MRL/lpr and 42 Treml4 −/− MRL/lpr mice were monitored without intervention until the time of death. Moribund mice were killed and were included as deaths in the analyses. Genotyping primer pairs for discriminating between Treml4 +/+ (WT) and Treml4 −/− (KO) mice were as follows (Fw, forward; Rv, reverse): WT Fw, 5′-CCCTTCCCAGTTCTGACTACC-3′; WT Rv, 5′-CAAACTCAGATAC TCATGCTGGCTGC-3′; KO Fw, 5′-GATCAGGATGATCTGGACGAA-3′; and KO Rv, 5′-CATCATTGATCCAGCTCCCTA-3′. The PCR product for the wildtype Treml4 allele is 449 bp and that for the mutated Treml4 allele is 1,257 bp. Genotyping primer pairs for discriminating between wild-type Fas and lpr were as follows: WT Fw, 5′-AGCATAGATTCCATTTGCT-3′, and WT Rv, 5′-AG TAATGGGCTCAGTGCA-3′; and lpr Fw, 5′-AGCATAGATTCCATTTGCT-3′, and lpr Rv, 5′-CAAATTTTATTGTTGCGACA-3′. PCR amplification conditions were as follows: 94 °C for 3 min; 30 cycles of 30 s each at 94 °C, 58 °C and 72 °C; followed by 7 min of incubation at 72 °C.
Isolation of BMDCs.
For the enrichment of BMDCs, mice were killed and bone marrow cells were collected from the femurs and tibiae. Following treatment with red blood cell lysis buffer (00-4333-57; eBioscience), the remaining cells were suspended at a final concentration of 1 × 10 6 cells/ml in complete RPMI medium supplemented with 10% supernatant of J558L mouse myeloma cells as a source of the cytokine GM-CSF. Cells were seeded in non-tissue culture-treated Petri dishes and incubated at 37 °C with 5% CO 2 , and cells were fed every 3 d. At day 8, cells were harvested and seeded according the experimental approach.
Purification of bone marrow-derived neutrophils. Marrow cavities of the femurs of 8-week-old mice were flushed with DMEM. After hypotonic lysis of red blood cells, mature neutrophils were isolated by centrifugation for 30 min at 28 °C and 500g over discontinuous Percoll gradients consisting of 55%, 65% and 75% (vol/vol) Percol in PBS. Mature neutrophils were recovered at the interface of the 65% and 75% fractions. Neutrophil purity was >90% as assessed by flow cytometry by staining with anti-Ly6G (RB6-8C5; eBioscience) and anti-CD11b (M1/70; eBioscience).
Pooled shRNA screen. The genome-scale pooled shRNA assays were performed with 2.5 × 10 7 RAW-GFP reporter cells for each replicate placed in culture medium containing 4 µg/ml polybrene and a pool of ~4 × 10 4 shRNAcontaining lentiviruses to achieve a multiplicity of infection of 0.3. After 24 h, the cells infected with that library were split into T175 flasks and were selected in culture medium containing puromycin. Five days later, 1 × 10 8 infected cells were treated for 6 h with GRD, then were harvested, stained with antibodies to detect intracellular TNF (MP6-XT22; R&D Systems) and sorted into two populations by flow cytometry on the basis of low and high dual expression of TNF and NF-κB-GFP. The shRNA sequences were amplified by PCR from the genomic DNA isolated from the sorted cells and were hybridized to complementary microarrays for analysis of the abundance of each shRNA with Dchip software.
